The State of the Biopharmaceutical Industry 2026 (Mid-Year Update) Edition

The biopharma industry entered 2026 facing a more complex and competitive environment shaped by macroeconomic uncertainty, geopolitical friction, and rapid advances in AI. While the sector has historically demonstrated resilience through economic cycles, companies are under growing pressure from pricing and reimbursement scrutiny, evolving regulatory expectations, potential tariff and supply-chain disruptions, and an increasing policy focus in the US. At the same time, the industry is confronting a significant patent cliff over the coming decade, intensifying the need to replenish pipelines, accelerate innovation, and secure growth through differentiated R&D and strategic dealmaking. These pressures are converging as global competition accelerates and capital allocation becomes increasingly selective. Innovation leadership is expanding geographically, particularly with the rise of China as a major source of biotech innovation and licensing activity, while investors continue to prioritize R&D productivity and commercial execution. In response, biopharma companies are sharpening their therapeutic area focus, investing in platform technologies, and pursuing targeted partnerships and acquisitions to offset future revenue erosion and sustain long-term growth in an increasingly competitive market.

• The report draws on a survey of pharma professionals, alongside GlobalData's market intelligence and analyst team, to benchmark sentiment on major industry themes for the next 12 months.
• Industry sentiment is cautiously optimistic for the next 12 months, with 55% of respondents being optimistic or very optimistic versus 10% of respondents being pessimistic. However, expectations remain below pre-2023 peaks.
• US tariffs and government actions are the single largest negative trend (cited by 69% of respondents), while personalized medicine (61%) and direct-to-patient sales (43%) lead the positive trends.
• MFN pricing and IRA negotiation are reshaping the US pricing landscape, with respondents ranking MFN (32%) and US import tariffs (31%) as the highest threats to near-term US pharma profitability.
• Innovation remains concentrated in oncology/hematology (rated 4.31 of 5) and metabolic disorders (4.11), with GLP-1RAs, ADCs, and bispecifics driving the strongest near-term commercial impact.
• AI integration is moving from pilots to function-specific deployment, with drug discovery and target identification (59%) and clinical trial design/recruitment (45%) cited as the highest-value use cases.
• China has shifted from being a "me-too" producer to a global innovation source, accounting for 22% of global drugs in development, with 58% of respondents viewing Chinese assets as a co-development opportunity.
• Biotech funding sentiment has improved, with 52% of respondents optimistic on recovery in the next 12 months, up from 39% in December 2025, supported by IPO market reopening, rising M&A activity, and a more favorable Federal Reserve posture.
• A patent cliff approaches, with only 4% of global sales under patent protection by 2030, while 10 near-term pre-registration drugs are forecast to reach or approach blockbuster status by 2032.

Scope

• Pinpoint the trends most likely to shape biopharma performance over the next 12 months across R&D, commercialization, and competitiveness.
• Gauge sentiment and confidence in the near-term outlook, including key opportunities and risks.
• Identify the biggest upside and downside drivers in market access and pricing, policy and geopolitical shifts, and regulatory change.
• Map therapy-area and modality momentum, highlighting where innovation and differentiated assets are gaining traction.
• Assess the pace and impact of AI adoption across discovery, development, manufacturing, and commercial functions.
• Track where innovation is emerging globally, including the role of China and other fast-moving hubs.
• Characterize deal and funding dynamics, including M&A direction, and capital allocation priorities.

Reasons to Buy

• Understand the business environment and the industry, regulatory, and macroeconomic trends shaping the biopharmaceutical industry in the next 12 months.
• Analyse the impact of major themes on the biopharmaceutical industry in the next 12 months.
• Identify themes that will have the greatest positive or negative impact in the coming months.
• Comprehend the opinions of industry respondents on these themes.